ArticleFrontiers in oncology2022

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.

Shuping Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.